In mouse models of non-CNS cancer, IL-6 blockade reduces the number of macrophages, myeloid cells, and Th17 cells and increases the number of effector T cells in the TIME, leading to therapeutic synergy when combined with ICI20. This evidence concerns the gene IL6 and central nervous system cancer.